Korean Medicine Health Insurance Expansion Exceeds Budget Estimates in Phase 2 Pilot Program
South Korea’s second phase of a pilot program expanding health insurance coverage for traditional herbal medicine (첩약) has exceeded initial financial projections by 60%, with 1.913 trillion won in payments made through June 2024, according to data from the National Health Insurance Service. The program, which added three new conditions—allergic rhinitis, functional dyspepsia, and lumbar disc herniation—to the 2020 pilot’s three initial conditions, saw utilization far surpass the government’s 1.188 trillion won estimate. The surge in costs stems from expanded eligibility to 12,000 medical facilities, including general hospitals, and broader patient access to 20-day treatment packages per condition annually.
Why This Matters
The financial overruns highlight tensions between expanding healthcare access and managing public funds. While the Korean Medical Association notes reduced out-of-pocket costs for patients with conditions like allergic rhinitis—where 30% co-payment rates apply at clinics—the Korean Medical Association has raised concerns about insufficient clinical evidence for the expanded treatments. The program’s 2026 end date means policymakers must address sustainability concerns before then, as the current trajectory could strain the national health insurance system.
What May Happen Next
Analysts expect the government to revise payment thresholds or restrict eligibility if costs continue rising. The Korean Medical Association has called for a comprehensive review of the program’s scope, while the Korean Medical Association has emphasized the need for more clinical trials to validate the treatments’ efficacy. A possible outcome is stricter criteria for approved conditions or a cap on annual treatment days per patient.
Did You Know? The herbal medicine insurance pilot program began in 2020 with three conditions—facial nerve paralysis, dysmenorrhea, and post-stroke sequelae—and expanded to six conditions in 2024.
Expert Insight: Samantha Carter, a healthcare policy analyst, notes that the program reflects broader global debates over integrating traditional medicine into public health systems. “While accessibility is a priority, the financial risks underscore the need for evidence-based scaling,” she says. “Without rigorous data, even well-intentioned policies can create long-term fiscal challenges.”
Frequently Asked Questions
Q. Which conditions are covered under the second-phase pilot? A. Allergic rhinitis, functional dyspepsia, lumbar disc herniation, along with the original conditions: facial nerve paralysis, dysmenorrhea, and post-stroke sequelae.
Q. How are treatment costs structured? A. Patients pay 30% co-pay at clinics, 40% at hospitals, and 50% at general hospitals, with a maximum of 20 days of treatment per condition annually.
Q. What happens after the pilot ends in 2026? A. The government will evaluate the program’s outcomes, with potential changes to coverage based on clinical evidence and financial sustainability.
How might balancing traditional medicine access with fiscal responsibility shape future healthcare policies in South Korea?